EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts

Basit Öğe Kaydı
dc.authoridŞALVA, EMINE/0000-0002-1159-5850
dc.authoridbasak, nese/0000-0001-5566-8321
dc.authorwosidŞALVA, EMINE/CAH-3062-2022
dc.authorwosidbasak, nese/ABH-5495-2020
dc.contributor.authorKehribar, Demet Yalcin
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorTurkmen, Nese Basak
dc.contributor.authorCiftci, Osman
dc.contributor.authorSalva, Emine
dc.contributor.authorOzgen, Metin
dc.date.accessioned2024-06-12T11:00:29Z
dc.date.available2024-06-12T11:00:29Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/aim: Epidermal growth factor receptor (EGFR) family members and their associated ligands may be related to bone and joint destruction in rheumatoid arthritis. Matrix metalloproteinases are responsible for joint and bone tissue degradation. This study is intended to investigate the effect of epidermal growth factor receptor inhibition by lapatinib on the synthesis of matrix metalloproteinases in in vitro. Materials and methods: Synovial fibroblast cell culture was obtained from a patient with rheumatoid arthritis who underwent knee arthroplasty. Interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) were added to the cell culture to stimulate synovial fibroblast cells and create an inflammatory character. Understimulated and nonstimulated conditions, lapatinib was applied to the culture in four different concentrations of 25, 50, 100, and 200 mu mol. Then, matrix metalloproteinase -1, -3, and, -13 levels were assessed. Results: When stimulated with IL-1 beta and TNF-alpha, the synthesis of matrix metalloproteinases from synovial fibroblast was increased significantly. When lapatinib is added to the stimulated synovial fibroblasts, matrix metalloproteinases synthesis is significantly suppressed. Conclusion: Inhibition of the EGFR pathway with lapatinib suppresses matrix metalloproteinases synthesis. Our results suggest EGFR pathway inhibition may be a promising option to prevent joint destruction in the treatment of rheumatoid arthritis.en_US
dc.description.sponsorshipRheumatology Education and Research Association [RAED-115]en_US
dc.description.sponsorshipThis project was supported by Rheumatology Education and Research Association (RAED-115).en_US
dc.identifier.doi10.55730/1300-0144.5442
dc.identifier.endpage1361en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid36326383en_US
dc.identifier.scopus2-s2.0-85136814255en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1355en_US
dc.identifier.trdizinid1144909en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5442
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1144909
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20860
dc.identifier.volume52en_US
dc.identifier.wosWOS:000881194200057en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpidermal Growth Factoren_US
dc.subjectLapatiniben_US
dc.subjectMatrix Metalloproteinaseen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectSynovial Fibroblasten_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectAngiogenesisen_US
dc.subjectCellsen_US
dc.subjectDestructionen_US
dc.subjectTargeten_US
dc.subjectModelen_US
dc.titleEGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblastsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu